Find the best therapeutic path
OPM’s culture is based on sharing, mutual assistance, community, sociability, and, more generally, solidarity.
OPM is a biopharmaceutical company specialized in precision medicine.
On 1 July 2022, Oncodesign announced the spin-off and transfer of its Biotech activity including AI to Oncodesign Precision Medicine (OPM).
With its diversified portfolio of technologies, molecules, and therapeutic targets, OPM has well and truly established its ability to discover active molecules for use against resistant and advanced cancers.
An innovative platform for selecting new therapeutic targets has been developed based on data obtained from patients and through an innovative approach using artificial intelligence (AI).
Two candidate drugs derived from Nanocyclix® technology are expected to enter the clinical phase in 2022. The first programme, resulting from a partnership with the Servier group, will commence its clinical phase in October 2022. The other, which aims to treat chronic immune-mediated inflammatory diseases, is scheduled to enter the clinical phase in December 2022.
Theranostics (the combination of “therapy” and “diagnostics”) has led to the most remarkable therapeutic progress observed over the last ten years in the treatment of advanced cancers. OPM shares in the extensive experience acquired by Oncodesign SA over the last 20 years, notably through its Pharmimage technology platform. This therapeutic approach has served to broaden OPM’s portfolio of new products, thanks to new biological vectorisation technology and effective targeting of metastatic cells.
Life is constantly adapting to new conditions. It innovates to keep going. We use our intelligence to move towards success.
